Hot Investor Mandate: China Based VC Invests Up to $30M in Therapeutics and Diagnostics Opportunities in North America with a Strong China Angle

3 Jan

A venture capital firm based in Hangzhou, China  makes early-growth stage investments, preferably in series A and B, but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune disease, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Capital Firm Invests in Therapeutics, Diagnostics, and Digital Health Technologies with Interests in Oncology, Immunology, and Diabetes

3 Jan

An investment firm with offices in the West and East Coasts invests in startups in highly regulated industries, including healthcare. The firm is interested in making investments at the seed and early venture stages; seed investments are typically $1-3 million. The firm invests globally.

The firm invests in digital health, and the firm is also interested in investing in early stage therapeutics. In the digital health space, the firm is primarily focused on technologies used by consumers/patients, and prefers to invest in companies that have revenues of at least $1 million or several customers and demonstrated product/market fit. In therapeutics, the firm is interested in preclinical technologies; the firm is open to investing in any therapeutic modality including cell and gene therapies. The firm is interested in oncology, immunology and diabetes, and will consider investing in other indication areas as well; however, antibiotics are not of interest. The firm may also consider investing in novel molecular diagnostics, provided there is a strong scientific component to the technology.

The firm is focused on investing in early stage companies, and typically invests in startups with under 15 staff. The firm focuses on finding the right team and the right science, and is interested in investing in early stage therapeutics in order to fund those companies through proof of concept studies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Over 500 Early Stage Investors Signed Up for RESI @ JPM

20 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Partnering is key. RESI is a dedicated partnering conference and will have 1400 meetings in one day. What is the salient difference between RESI and other conferences when it comes to partnering? RESI does not do the traditional “pay-to-pitch” on the podium to an unknown audience. We have found that the audience winds up being a mix of potential partners, other CEOs looking for competitive info and service providers wanting to sell their services. At RESI, when you sign up in our partnering system, investor profiles are highly detailed and tagged, allowing companies to perform searches and find the right investors and partners who are a fit for the companies’ stage of development and product set. This means you have a very high hit-rate on meetings because the RESI investors know that the firm making the request is a fit for their investment mandate.

At LSN, we vet all participating investors and do our best to ensure that those who attend are direct investors, not investment banks or broker-dealers. These global, cross-border, early-stage, from seed to series B, investors come to RESI to source technology assets for their pipelines and portfolios. RESI has helped over 350 companies raise over $500mm in the last three years. Click here to see who has already signed up.

%d bloggers like this: